<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14163">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327392</url>
  </required_header>
  <id_info>
    <org_study_id>3000-0523</org_study_id>
    <nct_id>NCT00327392</nct_id>
  </id_info>
  <brief_title>A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.</brief_title>
  <official_title>A Phase 3 Open-Label, Single Arm Study to Assess the Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal-to-Moderate Sedation in Patients Undergoing Minor Surgical Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Very often patients receive medications before a diagnostic, therapeutic, or surgical
      procedure to help them relax, keep them calm, and to relieve them from pain. This is called
      procedural sedation. With respect to minimal-to-moderate procedural sedation for minor
      surgical procedures, a patient is first given a pain-relief medication (analgesic) and then
      a medication to help him/her relax and keep calm (sedative). AQUAVAN is a chemically
      modified form of propofol, a commonly-used sedative drug. AQUAVAN acts like a slow release
      version of propofol, and is being studied to see if it can safely keep patients calm and
      relaxed during their medical procedure and then allow for rapid and clear-headed recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3 open-label, single-arm study designed to evaluate the safety of AQUAVAN
      following pretreatment with an analgesic, fentanyl, in patients who are undergoing minor
      surgical procedures that require minimal-to-moderate sedation. All patients will be placed
      on supplemental oxygen via nasal cannula and an electrocardiogram monitor, pulse oximeter,
      and blood pressure monitor will be attached prior to administration of fentanyl. Assessments
      will be made to evaluate the safety of AQUAVAN in patients undergoing minor surgical
      procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Incidence of Airway Assistance in Patients Undergoing Minor Surgical Procedures</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <enrollment type="Actual">123</enrollment>
  <condition>Procedural Sedation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQUAVAN® (fospropofol disodium) Injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        - Number of sites/patients: Approximately 18 sites and 125 patients.

        Inclusion Criteria:

          1. Patient must be able to understand, either orally or in writing, and be able to
             consent and complete the required assessments and procedures.

          2. Patient provides signed/dated Informed Consent and Health Insurance Portability and
             Accountability Act (HIPAA) of 1996 authorization after receiving a full explanation
             of the extent and nature of the study.

          3. Patient must be at least 18 years of age and undergoing one of the specified minor
             surgical procedures at the time of screening.

          4. If female, patient must be surgically sterile, postmenopausal, or not pregnant or
             lactating and must have been using an acceptable method of birth control for at least
             1 month prior to dosing, with a negative urine pregnancy test result at screening and
             predose.

          5. Patient meets American Society of Anesthesiologists (ASA) Physical Classification
             System status of P1 to P4.

        Exclusion Criteria:

          1. Patient has a history of allergic reaction or hypersensitivity to any anesthetic
             agent or opioid.

          2. Patient does not meet nils per os (NPO) status per ASA guidelines or institution's
             guideline.

          3. Patient has a Mallampati Classification Score of 4; or a Mallampati Classification
             Score of 3 and a thyromental distance &lt;4 cm, or for any other reason has a difficult
             airway, in the opinion of the Principal Investigator.

          4. Patient has an abnormal, clinically significant 3-lead ECG finding at predosing
             period.

          5. Patient has participated in an investigational drug study within 1 month prior to
             study start.

          6. Patient is unwilling to adhere to pre- and postprocedural instructions.

          7. Patient for whom the use of fentanyl citrate injection (fentanyl) is contraindicated.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James B Jones, MD, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Precision Trials</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Institute, Inc.</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Institute</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Women's Healthcare Group</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Heart Institute of Montana</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Urology, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Orthopaedic Sports Medicine</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians' Research Options</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 17, 2012</lastchanged_date>
  <firstreceived_date>May 16, 2006</firstreceived_date>
  <firstreceived_results_date>March 1, 2012</firstreceived_results_date>
  <keyword>Arthroscopy</keyword>
  <keyword>AV Shunt</keyword>
  <keyword>Bunion</keyword>
  <keyword>Dilatation and Curettage</keyword>
  <keyword>Esophagogastroduodenoscopy</keyword>
  <keyword>Hysteroscopy</keyword>
  <keyword>Lithotripsy</keyword>
  <keyword>Rotator Cuff/ Shoulder</keyword>
  <keyword>Transesophageal Echocardiography</keyword>
  <keyword>Ureteroscopy</keyword>
  <keyword>AQUAVAN</keyword>
  <keyword>Sedation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fospropofol</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study recruited at 12 study centers in the US during the period of 22-Jun-2006 to 01 Mar 2007.</recruitment_details>
      <pre_assignment_details>All subjects received fentanyl at an initial dose of 50 μg as an analgesic pretreatment 5 minutes prior to the administration of the initial dose of fospropofol disodium (also referred to as LUSEDRA and formerly known as AQUAVAN). After fentanyl administration, the venous catheter was flushed with 2 mL of sterile saline solution.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fospropofol Disodium</title>
          <description>Fospropofol disodium 6.5 mg/kg (no less than 390 mg and no more than 585 mg, based on age, weight, and American Society of Anesthesiologists [ASA] Status): one initial intravenous (i.v.) bolus dose. Supplemental doses of fospropofol disodium 1.63 mg/kg (no less than 97.5 mg and no more than 146 mg) were administered as needed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fospropofol Disodium</title>
          <description>Fospropofol disodium 6.5 mg/kg (no less than 390 mg and no more than 585 mg, based on age, weight, and American Society of Anesthesiologists [ASA] Status): one initial intravenous (i.v.) bolus dose. Supplemental doses of fospropofol disodium 1.63 mg/kg (no less than 97.5 mg and no more than 146 mg) were administered as needed.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="123"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51.3" spread="15.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="67"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>particpants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic/Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;60</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;60 to &lt;90</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;90</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologists (ASA) status</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>P1 ( A normal healthy patient )</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>P2 ( A patient with mild systemic disease )</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="67"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>P3 ( A patient with severe systemic disease )</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>P4 (High risk, severely compromised by disease)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Airway Assistance in Patients Undergoing Minor Surgical Procedures</title>
        <time_frame>2 hours</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of patients requiring specified types of airway assistance</population>
        <group_list>
          <group group_id="O1">
            <title>Fospropofol Disodium</title>
            <description>Fospropofol disodium 6.5 mg/kg (no less than 390 mg and no more than 585 mg, based on age, weight, and American Society of Anesthesiologists [ASA] Status): one initial intravenous (i.v.) bolus dose. Supplemental doses of fospropofol disodium 1.63 mg/kg (no less than 97.5 mg and no more than 146 mg) were administered as needed.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Airway Assistance in Patients Undergoing Minor Surgical Procedures</title>
            <units>particpants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Verbal Stimulation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loud Tone of Voice</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Face Mask</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chin Lift</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Oral Airway</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Increased Oxgen Flow</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fospropofol Disodium</title>
          <description>Fospropofol disodium 6.5 mg/kg (no less than 390 mg and no more than 585 mg, based on age, weight, and American Society of Anesthesiologists [ASA] Status): one initial intravenous (i.v.) bolus dose. Supplemental doses of fospropofol disodium 1.63 mg/kg (no less than 97.5 mg and no more than 146 mg) were administered as needed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ammonia increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine spasm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Medical Services</name_or_title>
      <organization>Eisai Inc</organization>
      <phone>1-888-422-4743</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
